A Phase II Trial of Poly-ICLC for Low-Grade Gliomas — NF111  

Low-grade Glioma Clinical Trial

Official title: A Phase II Trial of Poly-ICLC for Progressive, Previously Treated Low-Grade Gliomas in Children and Young Adults With Neurofibromatosis Type 1

Status Recruiting

Clinical Trial Summary

This is a phase II, prospective, longitudinal, multi-center trial of poly-ICLC (Hiltonol ®) treatment for progressive low-grade gliomas in pediatric patients with NF1. The primary objective is to evaluate the efficacy of poly-ICLC in pediatric NF1 patients with progressive low-grade glioma (LGG) as measured by objective tumor response rate (CR+PR) within the first 48 weeks (12 cycles) of therapy. There will also be secondary and exploratory objectives listed in the detailed description below.

Clinical Trial Description

This is a phase II, prospective, longitudinal, multi-center trial of poly-ICLC (Hiltonol ®) treatment for progressive low-grade gliomas in pediatric patients with NF1. The primary objective is to evaluate the efficacy of poly-ICLC in pediatric NF1 patients with progressive low-grade glioma (LGG) as measured by objective tumor response rate (CR+PR) within the first 48 weeks (12 cycles) of therapy. The secondary objectives are to: 1. Determine 12, 24 and 60 month progression free survival (PFS) in pediatric NF1 patients with progressive LGG treated with poly-ICLC. 2. Evaluate the efficacy of poly-ICLC in pediatric NF1 patients with progressive LGG as measured by best objective tumor response rate (CR+PR) within 24 cycles of therapy. 3. Evaluate the efficacy of poly-ICLC in pediatric NF1 patients with progressive LGG as measured by clinical benefit response rate (CR+PR+MR+SD) after 12 and 24 cycles of therapy. 4. Assess the toxicity associated with poly-ICLC treatment in pediatric NF1 patients with LGG. Exploratory objectives are to: 1. Evaluate the visual outcome measures in children with progressive optic pathway gliomas treated with poly-ICLC. Visual response is defined as 0.2 logMAR or greater in acuity improvement. 2. Evaluate patient reported outcomes and quality of life measures. 3. Evaluate biological correlates. ;

Related Conditions & MeSH terms

• Glioma
• Low-grade Glioma
• NF1

• NCT number: NCT04544007
• Study type: Interventional
• Source: University of Alabama at Birmingham
• Contact: Bruce R Korf, MD, PhD
• Phone: 205.934.9410
• Email: bkorf@uabmc.edu
• Status: Recruiting
• Phase: Phase 2
• Start date: December 15, 2021
• Completion date: February 15, 2027